Manufacturers and pharmacies seem to be trying to justify their continued compounding by adding in extra ingredients like B vitamins so the drugs arent exact copies (In a note, Eli Lilly recently warned about potential impurity risks of compounds that do this)
Commit to a full four-week trial before judging effectiveness
Berg said, is that when the trial recruited patients, many of them had small, undiagnosed lung tumors, which progressed more rapidly when they were given antioxidants
And research supports this: A small study found that both aerobic activity and resistance training significantly improved skin elasticity
However, since the GLP-1 receptor is expressed in many tissues beyond its primary target (e.g., the brain, heart, and lungs), current research aims to investigate the comprehensive systemic effects of these drugs, particularly on cancer
MariTide is in Phase 3 trials, although results are not expected until 2027 which would put commercialisation behind some of the other GLP-1 contenders in the pipeline
